EuroBiotech Report: Addiction data, J&J-Genmab, Basilea rejig, Zealand, CRUK and more

europeGOOD

Welcome to the latest edition of our weekly EuroBiotech Report. Indivior (LON:INDV) took a big step toward bringing its once-a-month opioid dependence drug to market. The Reckitt Benckiser (LON:RB) spinout reported Phase III data on the program, sending its stock up 15% and positioning it to snag an approval by the end of 2017. Johnson & Johnson ($JNJ) and Genmab (CPH:GEN) are hoping to get their latest trip to FDA wrapped up much sooner. The pair are waiting on a priority review decision that could lead to the label for Darzalex being expanded in the coming months. Zealand Pharma (CPH:ZEAL) is also gearing up for talks with FDA. The Danish drugmaker wants to meet with the regulator to discuss Phase II data on its rival to Novo Nordisk’s ($NVO) GlucaGen. Basilea Pharmaceutica (SWX:BSLN) rejigged its early-stage pipeline, dropping an inhaled antibiotic while expanding a trial of its small molecule tumor checkpoint controller. Cancer Research UK began a Phase I/II bladder cancer trial of Astex Pharmaceuticals’ DNA methyltransferase inhibitor. And more.

1. Late-phase opioid addiction success sparks surge in Indivior stock price 

2. J&J files to expand Darzalex label, triggering another payout to Genmab

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

3. Zealand takes PhII data to FDA after going up against Novo’s incumbent

4. Basilea drops inhaled antibiotic, expands cancer program in early-stage rejig

5. CRUK pairs Astex's inhibitor with chemo for bladder cancer trial

And more articles of note >>

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.